ProQR Therapeutics N.V. - Ordinary Shares (PRQR): Price and Financial Metrics


ProQR Therapeutics N.V. - Ordinary Shares (PRQR): $0.68

-0.13 (-16.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRQR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRQR POWR Grades


  • Growth is the dimension where PRQR ranks best; there it ranks ahead of 64.23% of US stocks.
  • The strongest trend for PRQR is in Value, which has been heading up over the past 179 days.
  • PRQR ranks lowest in Stability; there it ranks in the 4th percentile.

PRQR Stock Summary

  • PRQR's price/sales ratio is 26.74; that's higher than the P/S ratio of 94.2% of US stocks.
  • Revenue growth over the past 12 months for ProQR Therapeutics NV comes in at -75.5%, a number that bests only 1.63% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PRQR comes in at -187.85% -- higher than that of only 1.63% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ProQR Therapeutics NV are CGEN, FULC, WVE, SRPT, and SURF.
  • PRQR's SEC filings can be seen here. And to visit ProQR Therapeutics NV's official web site, go to www.proqr.com.

PRQR Price Target

For more insight on analysts targets of PRQR, see our PRQR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.19 Average Broker Recommendation 1.31 (Strong Buy)

PRQR Stock Price Chart Interactive Chart >

Price chart for PRQR

PRQR Price/Volume Stats

Current price $0.68 52-week high $9.09
Prev. close $0.81 52-week low $0.53
Day low $0.68 Volume 734,300
Day high $0.85 Avg. volume 1,392,113
50-day MA $0.71 Dividend yield N/A
200-day MA $4.33 Market Cap 48.48M

ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Company Bio


ProQR Therapeutics is a biopharmaceutical company, focused on RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. The company was founded in 2012 and is based in Leiden, the Netherlands.


PRQR Latest News Stream


Event/Time News Detail
Loading, please wait...

PRQR Latest Social Stream


Loading social stream, please wait...

View Full PRQR Social Stream

Latest PRQR News From Around the Web

Below are the latest news stories about ProQR Therapeutics NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.

ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; interim data readout from Helia extension study of ultevursen planned by year-end 2022Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial data from m

Yahoo | February 24, 2022

Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should Know

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Why ProQR Therapeutics Stock Got Slammed Again Monday

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

Yahoo | February 14, 2022

ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

Yahoo | February 14, 2022

Read More 'PRQR' Stories Here

PRQR Price Returns

1-mo 6.58%
3-mo -24.03%
6-mo -91.69%
1-year -90.46%
3-year -92.69%
5-year -86.53%
YTD -91.51%
2021 90.71%
2020 -57.62%
2019 -37.20%
2018 389.30%
2017 -34.18%

Continue Researching PRQR

Here are a few links from around the web to help you further your research on ProQR Therapeutics NV's stock as an investment opportunity:

ProQR Therapeutics NV (PRQR) Stock Price | Nasdaq
ProQR Therapeutics NV (PRQR) Stock Quote, History and News - Yahoo Finance
ProQR Therapeutics NV (PRQR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4455 seconds.